SGLT2 Inhibitor Amputation Risk Seen in Real-World Diabetes Study

Sodium-glucose cotransporter 2 (SGLT2) inhibitors, increasingly used in the treatment of type 2 diabetes, show as much as a twofold increase in the risks of lower limb amputations and diabetic ketoacidosis compared with glucagon-like peptide 1 (GLP-1) re https://www.medscape.com/viewarticle/904912